Key result
Riociguat earns FDA approval for adult PAH based on the PATENT-1 study.
Why the study?
Does riociguat treat pulmonary arterial hypertension in adults?
Does riociguat treat pulmonary arterial hypertension in adults?
Riociguat is a novel soluble guanylate cyclase stimulator that has received FDA approval for the treatment of pulmonary arterial hypertension in adults.
Riociguat approval expands adult PAH options; leaves open comparative effectiveness and long-term outcomes.
Stimulators of soluble guanylate cyclase (sCG) are novel pharmacological agents that directly stimulate sGC. Ongoing research on sGC stimulators led to the development of the more potent and more specific sGC stimulator, riociguat. Recently, the US Food and Drug Administration has approved riociguat to treat pulmonary arterial hypertension in adults. Support for the approval of riociguat comes from the recently published PATENT-1 (Pulmonary Arterial Hypertension Soluble Guanylate Cyclase-Stimulator Trial 1) study.
No takes yet. Share an insight, caveat, or question.
Karim Said (2014) conducted a review in Pulmonary arterial hypertension. Riociguat was evaluated. The US Food and Drug Administration has approved the soluble guanylate cyclase stimulator riociguat for the treatment of pulmonary arterial hypertension in adults based on the PATENT-1 study.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: